Transglutaminase inhibitor cystamine alleviates the abnormality in liver from NZB/W F1 mice
Authors:
- Tsai-Ching HsuTHTsai-Ching Hsu
- Chih-Yang HuangCHChih-Yang Huang
- Szu-Yi ChiangSCSzu-Yi Chiang
- Wen-Xian LaiWLWen-Xian Lai
- Chang-Hai TsaiCTChang-Hai Tsai
- Bor-Show TzangBTBor-Show Tzang
- 1 January 2008
- journal article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 579 (1-3) , 382-389
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Removal of dying cells and systemic lupus erythematosusModern Rheumatology, 2005
- Hepatic manifestations of autoimmune rheumatic diseasesAnnals of the Rheumatic Diseases, 2004
- Aspirin and NS-398 inhibit hepatocyte growth factor-induced invasiveness of human hepatoma cellsHepatology, 2002
- Autoimmunity to the p53 Protein is a Feature of Systemic Lupus Erythematosus (SLE) Related to Anti-DNA AntibodiesJournal of Autoimmunity, 2001
- Selective cyclooxygenase-2 inhibitors for the treatment of arthritisClinical Therapeutics, 1999
- Selective Cyclooxygenase-2 Inhibitors as Potential Therapeutic Agents for Inflammatory Diseases1997
- Noncytotoxic alkyl-lysophospholipid treatment increases sensitivity of leukemic K562 cells to lysis by natural killer (NK) cellsInternational Journal of Cancer, 1996
- Differential heat shock protein overexpression and its clinical relevance in systemic lupus erythematosus.Annals of the Rheumatic Diseases, 1993
- TransglutaminasesAnnual Review of Biochemistry, 1980
- SUPPRESSION OF COOMBS-POSITIVE HÆMOLYTIC ANAEMIA IN NZB MICE BY ANTILYMPHOCYTE GLOBULINThe Lancet, 1967